Ruthenium dihydroxybipyridine complexes are tumor activated prodrugs due to low pH and blue light induced ligand release
Kyle T. Hufziger, Fathima Shazna Thowfeik, David J. Charboneau, Ismael Nieto, William G. Dougherty, W. Scott Kassel, Timothy J. Dudley, Edward J. Merino, Elizabeth T. Papish, Jared J. Paul
Dive into the research topics of 'Ruthenium dihydroxybipyridine complexes are tumor activated prodrugs due to low pH and blue light induced ligand release'. Together they form a unique fingerprint.